LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Kodu・Aktsiate loetelu・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Suletud

SektorTervishoid

297.33 -0.94

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

295.6

Max

297.51

Põhinäitajad
By Trading Economics
Sissetulek	20M 206M
Müük	70M 1.2B
P/E Sektori keskmine	71.927 49.701
Aktsiakasum	1.99
Kasumimarginaal	17.649
Töötajad	2,500
EBITDA	7.1M 152M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+50.12% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-2.9B 38B
Eelmine avamishind	298.27
Eelmine sulgemishind	297.33

Uudiste sentiment

By Acuity

50%

159 / 345 Pingereas Healthcare

Alnylam Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. mai 2026, 08:24 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25. mai 2026, 21:22 UTC

Tulu

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25. mai 2026, 20:50 UTC

Market Talk

Tulu

Basic Materials Roundup: Market Talk

25. mai 2026, 16:20 UTC

Market Talk

Tulu

Basic Materials Roundup: Market Talk

25. mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25. mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25. mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25. mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25. mai 2026, 12:56 UTC

Market Talk

Tulu

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25. mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25. mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25. mai 2026, 12:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero's Assets Look Strategic -- Market Talk

25. mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25. mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25. mai 2026, 10:05 UTC

Tulu

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25. mai 2026, 10:04 UTC

Tulu

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25. mai 2026, 10:03 UTC

Tulu

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25. mai 2026, 10:02 UTC

Tulu

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25. mai 2026, 10:01 UTC

Tulu

Tenaga Nasional 1Q Net Up 3.7% on Year

25. mai 2026, 10:00 UTC

Tulu

Tenaga Nasional 1Q Rev Up 6.6% on Year

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q EPS MYR0.1883

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q Rev MYR17.1B

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q Net MYR1.1B

25. mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25. mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25. mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25. mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Alnylam Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

50.12% tõus

12 kuu keskmine prognoos

Keskmine 446.53 USD 50.12%

Kõrge 550 USD

Madal 330 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Alnylam Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

Osta

Hoia

Müü

Põhineb 20 analüütiku instrumendi Alnylam Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

159 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.